Angiogenesis and Fibrogenesis in Chronic Liver Diseases

Cellular and Molecular Gastroenterology and Hepatology

Volumn 1, Issue 5, 2015, Pages 477-488

  Bocca, Claudia ^a   Novo, Erica ^a   Miglietta, Antonella ^a   Parola, Maurizio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Hypoxia; Liver Angiogenesis; Liver Fibrogenesis; Myofibroblasts

Indexed keywords

HYPOXIA INDUCIBLE FACTOR;

ANGIOGENESIS; CHRONIC LIVER DISEASE; DISEASE COURSE; ENDOTHELIUM CELL; FIBROGENESIS; HUMAN; HYPOXIA; INFLAMMATION; LIVER SINUSOID; MACROPHAGE; MEMBRANE MICROPARTICLE; MYOFIBROBLAST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STELLATE CELL; VASCULAR REMODELING;

EID: 84939239888     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2015.06.011     Document Type: Review

References (105)

1. Medina J., Arroyo A.G., Sánchez-Madrid F., Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004, 39:1185-1195.
2. Lee J.S., Semela D., Iredale J., et al. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte?. Hepatology 2007, 45:817-825.
3. Fernández M., Semela D., Bruix J., et al. Angiogenesis in liver disease. JHepatol 2009, 50:604-620.
4. Valfrè di Bonzo L., Novo E., Cannito S., et al. Angiogenesis and liver fibrogenesis. Histol Histopathol 2009, 23:1324-1341.
5. Elpek G.Ö. Angiogenesis and liver fibrosis. World J Hepatol 2015, 7:377-391.
6. Bosch J., Abraldes J.G., Fernández M., et al. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. JHepatol 2010, 53:558-567.
7. Zhang D.Y., Friedman S.L. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012, 56:769-775.
8. Kocabayoglu P., Friedman S.L. Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) 2013, 5:217-230.
9. Parola M., Marra F., Pinzani M. Myofibroblast-like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario. Mol Asp Med 2008, 29:59-67.
10. Rosmorduc O., Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010, 30:258-270.
11. Novo E., Cannito S., Paternostro C., et al. Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys 2014, 548:20-37.
12. Cannito S., Paternostro C., Busletta C., et al. Hypoxia, hypoxia-inducible factors and fibrogenesis in chronic liver diseases. Histol Histopathol 2014, 29:33-44.
13. Fernandez M. Molecular pathophysiology of portal hypertension. Hepatology 2015, 61:1406-1415.
14. Povero D., Eguchi A., Niesman I.R., et al. Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells. Sci Signal 2013, 6:ra88.
15. Lemoinne S., Cadoret A., Rautou P.E., et al. Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. Hepatology 2015, 61:1041-1055.
16. Nath B., Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology 2012, 55:622-633.
17. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008, 88:125-172.
18. Kisseleva T., Brenner D.A. The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis. J Hepatol 2012, 56:965-972.
19. Lee U.E., Friedman S.L. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011, 25:195-206.
20. Forbes S.J., Parola M. Liver fibrogenic cells. Best Pract Res Clin Gastroenterol 2011, 25:207-218.
21. Mederacke I., Hsu C.C., Troeger J.S., et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nature Commun 2013, 4:2823.
22. Dranoff J.A., Wells R.G. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatology 2010, 51:1438-1444.
23. Camenisch G., Pisabarro M.T., Sherman D., et al. ANGPTL3 stimulates endothelial cell adhesion and migration via integrin avβ3 and induces blood vessel formation invivo. JBiol Chem 2002, 277:17281-17290.
24. Coch L., Mejias M., Berzigotti A., et al. Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats. Hepatology 2014, 60:633-647.
25. Semenza G.L. Oxygen sensing, homeostasis and disease. NEngl J Med 2011, 365:537-547.
26. Semenza G.L. Hypoxia inducible factors in physiology and medicine. Cell 2012, 148:399-408.
27. Zhang Z., Zhang F., Lu Y., Zheng S. Update on implications and mechanisms of angiogenesis in liver fibrosis. Hepatol Res 2015, 45:162-178.
28. Corpechot C., Barbu V., Wendum D., et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002, 35:1010-1021.
29. Novo E., Cannito S., Zamara E., et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007, 170:1942-1953.
30. Novo E., Povero D., Busletta C., et al. The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. JPathol 2012, 226:588-597.
31. Moon J.O., Welch T.P., Gonzalez F.J., et al. Reduced liver fibrosis in hypoxia-inducible factor-1 alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol 2009, 296:G582-G592.
32. Tugues S., Fernandez-Varo G., Muñoz-Luque J., et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007, 46:1919-1926.
33. Majumder S., Piguet A.C., Dufour J.F., Chatterjee S. Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. Eur J Pharmacol 2013, 705:86-95.
34. Mejias M., Garcia-Pras E., Tiani C., et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009, 49:1245-1256.
35. Yoshiji H., Kuriyama S., Yoshii J., et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003, 52:1347-1354.
36. Van Steenkiste C., Ribera J., Geerts A., et al. Inhibition ofplacental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology 2011, 53:1629-1640.
37. Taura K., De Minicis S., Seki E., et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008, 135:1729-1738.
38. Sahin H., Borkham-Kamphorst E., Kuppe C., et al. Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology 2012, 55:1610-1619.
39. Huang H.C., Wang S.S., Hsin I.F., et al. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. Hepatology 2012, 56:248-258.
40. Reichenbach V., Ros J., Fernández-Varo G., et al. Prevention of fibrosis progression in CCl4-treated rats: role of the hepatic endocannabinoid and apelin systems. JPharmacol Exp Ther 2012, 340:629-637.
41. Liu Y., Wang Z., Wang J., et al. Ahistone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling. Liver Int 2013, 33:504-515.
42. Zhu Q., Zou L., Jagavelu K., et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. JHepatol 2012, 56:893-899.
43. Thabut D., Routray C., Lomberk G., et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 2011, 54:573-585.
44. Fernandez M., Vizzutti F., Garcia-Pagan J.C., et al. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004, 126:886-894.
45. Fernandez M., Mejias M., Angermayr B., et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. JHepatol 2005, 43:98-103.
46. Fernandez M., Mejias M., Garcia-Pras E., et al. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 2007, 46:1208-1217.
47. Mejias M., Garcia-Pras E., Tiani C., et al. The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats. JCell Mol Med 2008, 12:1690-1699.
48. Tiani C., Garcia-Pras E., Mejias M., et al. Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. JHepatol 2009, 50:296-305.
49. Mejias M., Coch L., Berzigotti A., et al. Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats. Gut 2015, 64:657-666.
50. Patsenker E., Popov Y., Stickel F., et al. Pharmacological inhibition of integrin αvβ3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009, 50:1501-1511.
51. Kantari-Mimoun C., Castells M., Klose R., et al. Resolution of liver fibrosis requires myeloid cell-driven sinusoidal angiogenesis. Hepatology 2015, 61:2042-2055.
52. Coriat R., Gouya H., Mir O., et al. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS One 2011, 6:e16978.
53. Shah V.H., Bruix J. Antiangiogenic therapy: not just for cancer anymore?. Hepatology 2009, 49:1066-1068.
54. Duffy A., Wilkerson J., Greten T.F. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology 2013, 57:1068-1077.
55. Yang L., Kwon J., Popov Y., et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 2014, 146:1339-1350.
56. Coulon S., Heindryckx F., Geerts A., et al. Angiogenesis in chronic liver disease and its complications. Liver Int 2011, 31:146-162.
57. Capece D., Fischietti M., Verzella D., et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int 2013, 2013:187-204.
58. Matsubara T., Kanto T., Kuroda S., et al. TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology 2013, 57:1416-1425.
59. Solinas G., Germano G., Mantovani A., et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. JLeukoc Biol 2009, 86:1065-1073.
60. Tacke F. Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liverfibrosis invivo. Fibrogenesis Tissue Repair 2012, 5(Suppl 1):S27.
61. Ehling J., Bartneck M., Wei X., et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 2014, 63:1960-1971.
62. Iwakiri Y., Grisham M., Shah V. Vascular biology and pathobiology of the liver: report of a single-topic symposium. Hepatology 2008, 47:1754-1763.
63. Iwakiri Y., Shah V., Rockey D.C. Vascular pathobiology in chronic liver disease and cirrhosis-current status and future directions. JHepatol 2014, 61:912-924.
64. Geerts A. History, heterogeneity, developmental biology and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001, 21:311-335.
65. Pinzani M., Failli P., Ruocco C., et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. JClin Invest 1992, 90:642-646.
66. Clemens M.G., Zhang J.X. Regulation of sinusoidal perfusion: invivo methodology and control by endothelins. Semin Liver Dis 1999, 19:383-393.
67. Kawada N., Kuroki T., Kobayashi K., et al. Action of endothelins on hepatic stellate cells. JGastroenterol 1995, 30:731-738.
68. Pinzani M., Milani S., De Franco R., et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996, 110:534-548.
69. Rockey D.C., Weisiger R.A. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996, 24:233-240.
70. Mallat A., Preaux A.M., Serradeil-Le G., et al. Growth inhibitory properties of endothelin-A in activated human stellate cells: a cyclic adenosine monophosphate-mediated pathway. JClin Invest 1996, 98:2771-2778.
71. Shah V., Haddad F.G., Garcia-Cardena G., et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. JClin Invest 1997, 100:2923-2930.
72. Jarnagin W.R., Rockey D.C., Koteliansky V.E., et al. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. JCell Biol 1994, 127:2037-2048.
73. Rockey D.C., Fouassier L., Chung J.J., et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 1998, 27:472-480.
74. 2+-calmodulin and caveolin. JBiol Chem 1997, 272:15583-15586.
75. Fulton D., Gratton J.P., McCabe T.J., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601.
76. Langer D.A., Das A., Semela D., et al. Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology 2008, 47:1983-1993.
77. Deleve L.D., Wang X., Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology 2008, 48:920-930.
78. Rockey D.C., Chung J. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. JClin Invest 1995, 95:1199-1206.
79. Ding B.S., Nolan D.J., Butler J.M., et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 2010, 468:310-315.
80. Wang L., Wang X., Xie G., et al. Liver sinusoidal endothelial cell progenitor cells promote liver regeneration in rats. JClin Invest 2012, 122:1567-1573.
81. Ding B.S., Cao Z., Lis R., et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature 2014, 505:97-102.
82. Ankoma-Sey V., Wang Y., Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 2000, 31:141-148.
83. Wang Y.Q., Luk J.M., Ikeda K., et al. Regulatory role of vHL/HIF-1α in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun 2004, 317:358-362.
84. Aleffi S., Petrai I., Bertolani C., et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005, 42:1339-1348.
85. Copple B.L., Bai S., Burgoon L.D., et al. Hypoxia-inducible factor-1α regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int 2011, 31:230-244.
86. Novo E., Busletta C., Bonzo L.V., et al. Intracellular reactive oxygen species are required for directional migration ofresident and bone marrow-derived hepatic pro-fibrogenic cells. JHepatol 2011, 54:964-974.
87. Busletta C., Novo E., Valfrè Di Bonzo L., et al. Dissection of the biphasic nature of hypoxia-induced motogenic action in bone marrow-derived human mesenchymal stem cells. Stem Cells 2011, 29:952-963.
88. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
89. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
90. Nyberg P., Xie L., Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005, 65:3967-3979.
91. Watanabe K., Hasegawa Y., Yamashita H., et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. JClin Invest 2004, 114:898-907.
92. Chatterjee S. Reversal of vasohibin-driven negative feedback loop of vascular endothelial growth factor/angiogenesis axis promises a novel antifibrotic therapeutic strategy for liver diseases. Hepatology 2014, 60:458-460.
93. Principe A., Melgar-Lesmes P., Fernández-Varo G., et al. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology 2008, 48:1193-2001.
94. Yokomori H., Oda M., Yoshimura K., et al. Overexpression of apelin receptor (APJ/AGTRL1) on hepatic stellate cells and sinusoidal angiogenesis in human cirrhotic liver. JGastroenterol 2011, 46:222-231.
95. Melgar-Lesmes P., Casals G., Pauta M., et al. Apelin mediates the induction of profibrogenic genes in human hepatic stellate cells. Endocrinology 2010, 151:5306-5314.
96. Kitade M., Yoshiji H., Kojima H., et al. Leptin-mediated neovascularization is a prerequisite for progression of non-alcoholic steatohepatitis in rats. Hepatology 2006, 44:983-991.
97. Semela D., Das A., Langer D., et al. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology 2008, 135:671-679.
98. Aleffi S., Navari N., Delogu W., et al. Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2011, 301:G210-G219.
99. Copple B.L., Kaska S., Wentling C. Hypoxia-inducible factor activation in myeloid cells contributes to the development of liver fibrosis in cholestatic mice. JPharmacol Exp Ther 2012, 341:307-316.
100. Morel O., Morel N., Jesel L., et al. Microparticles: A critical component in the nexus between inflammation, immunity, and thrombosis. Semin Immunopathol 2011, 33:469-486.
101. Rautou P.E., Vion A.C., Amabile N., et al. Microparticles, vascular function, and atherothrombosis. Circ Res 2011, 109:593-606.
102. Rautou P.E., Bresson J., Sainte-Marie Y., et al. Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology 2012, 143:166-176.
103. Witek R.P., Yang L., Liu R., et al. Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology 2009, 136:320-330.
104. Kornek M., Lynch M., Mehta S.H., et al. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology 2012, 143:448-458.
105. Lemoinne S., Thabut D., Housset C., et al. The emerging roles of microvesicles in liver diseases. Nat Rev Gastroenterol Hepatol 2014, 11:350-361.